Phase I Randomized Trial of Stereotactic Body Radiotherapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma.

Aditya Juloori,Rohan R Katipally,Jeffrey M Lemons,Anurag K Singh,Renuka Iyer,Jared R Robbins,Ben George,William A Hall,Sean P Pitroda, Fauzia Arif,John Fung,Anjana Pillai,Chih-Yi Liao,Manish Sharma,Stanley L Liauw

International journal of radiation oncology, biology, physics（2022）

引用 9|浏览11

暂无评分

摘要

In this first prospective trial investigating the combination of SBRT and immunotherapy for HCC, multi-modal therapy demonstrated acceptable safety. SBRT with nivolumab plus ipilimumab compared favorably to outcomes of immunotherapy alone and warrants further investigation.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要